Thirteen months after Merck agreed to pay $100 million to settle litigation over the NuvaRing contraceptive, not a single active case remains in New Jersey.
Meanwhile, lawyers for the plaintiffs acknowledged that the settlement, which must be divided among thousands of claimants, is not as large as they had hoped but said it was as good as they could get, given the difficulty in proving liability.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
